Oaktree Acquisition Corp. III Life Sciences
| IPO Proceeds, $M | $175.00M |
|---|---|
| IPO Date | Oct 24, 2024 |
| CEO | Zaid Pardesi |
| Left Lead | Jefferies |
| IPO Cash in Trust | 100.0% |
| SPAC Tenor | 24 months |
| IPO Sector |
Healthcare
North American, British or European companies in the biopharmaceutical, medical devices, diagnostics, and specialized healthcare services sectors |
| IPO Geography | Global |
| Target Company | TBD |
| Deal Announced | TBD |
| Deal Size, $M | TBD |
| Deal Sector | TBD |
| Deal Geography | TBD |
| SEC Filings | www.sec.gov |
| Approval Vote | TBD |
| Amendment Vote | TBD |
| Price | $9.99 |
|---|---|
| Last closing price | $10.00 |
| H/L, today | $9.99 / $9.99 |
| Volume, today | 52,100 |
| Volume, 3-month avg. | N/A |
No credit card required
Sign in for more on Oaktree Acquisition Corp. III Life Sciences:
- Structure and cap table
- 6 directors & officers
- 5 filings and events
- 3 underwriters
Structure
Sign in to view structure, cap table, and calendar of events.
Team
| Name | Age | Title |
|---|---|---|
| Zaid Pardesi | 41 | Chief Executive Officer & Director |
| Aman Kumar | 44 | Chairman & Director |
| Mathew Pendo | 61 | Chief Operating Officer |
| Courtney Conigliaro | 43 | Chief Financial Officer |
| Paul Meister | 71 | Director |
| Alvin Shih | 47 | Director |
Sign in to view team biographies and more sponsor and affiliate data.
Advisors
Filings
| Oct 4, 2024 | Initial S-1 |
| Oct 23, 2024 |
PR announcing pricing of $175mm IPO
Sign In to view filing content. |
| Oct 24, 2024 | 424B4 IPO Prospectus |
| Dec 11, 2024 |
8-K announcing separate trading of shares and warrants
Sign In to view filing content. |
| Jan 7, 2025 |
8-K announcing change in directors
Sign In to view filing content. |